New Delhi: Takeda Biopharmaceuticals India Pvt Ltd on Monday said it has received market authorisation from the Drug Controller General of India (DCGI) for dengue prevention vaccine, QDENGA.
QDENGA, the first dengue vaccine approved in India, is used for the prevention of dengue in individuals aged 4-60 years. It can be administered regardless of previous dengue exposure, without the need for pre-vaccination testing, said the company, an arm of Japan's Biopharmaceuticals major Takeda, in a statement.
